<DOC>
	<DOCNO>NCT02453997</DOCNO>
	<brief_summary>This study investigate mycophenic acid ( MPA ) pharmacokinetics pharmacogenomics impact clinical outcome lupus nephritis ( LN ) patient . Lupus nephritis patient ( active inactive ) recruit . MPA level check 1 , 2 , 4 , 8 , 10 , 12 hr MMF administration enzymatic assay upon recruitment , 6-months ' interval also clinically significant event occur . The MPA level correlate clinical parameter outcomes . Pharmacogenomics study also carry correlated MPA exposure clinical outcome .</brief_summary>
	<brief_title>Mycophenolic Acid Pharmacokinetics Pharmacogenomics Lupus Nephritis</brief_title>
	<detailed_description>This study investigate mycophenic acid ( MPA ) pharmacokinetics pharmacogenomics impact clinical outcome lupus nephritis ( LN ) patient . Lupus nephritis patient ( active inactive ) recruit . MPA level check 1 , 2 , 4 , 8 , 10 , 12 hr MMF administration enzymatic assay upon recruitment , 6-months ' interval also clinically significant event occur . The MPA level correlate clinical parameter outcome . For active patient , MPA level correlate treatment response ( CR PR ) side effect . For patient remission , MPA level correlate drug tolerability relapse . Pharmacogenomics study also carry correlated MPA exposure clinical outcome .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Patients recent active LN ( biopsyproven Class III/IV+/V LN accord ISN/RPS 2003 classification within 3 month , proteinuria &gt; 0.5 g/day and/or active urinary sediment ) receive corticosteroid MMF ( 1g bd 6 month ) induction treatment . 2 . LN patient remission ( define proteinuria &lt; 0.5 g/day inactive urinary sediment , prednisolone &lt; 10 mg/day ) stable MMF maintenance ( dose unchanged within previous 3 month ) . 1 . Patients receive entericcoated mycophenolic acid ( myfortic ) . 2 . Patients receive concomitant calcineurin inhibitor ( e.g . cyclosporine tacrolimus ) corticosteroid MMF . 3 . Patients receive concomitant medication affect MPA pharmacokinetics cholestyramine , acyclovir , rifampicin . 4 . Patients pregnant lactate . 5 . Patients gastric empty disorder 6 . Patients hepatic biliary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>lupus nephritis</keyword>
	<keyword>mycophenolic acid</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacogenomics</keyword>
</DOC>